Pharmacological, Biochemical and Therapeutic Potential of Milk Thistle (Silymarin): A Review
暂无分享,去创建一个
[1] Didunyemi Mo,et al. Morinda lucida Attenuates Acetaminophen-Induced Oxidative Damage and Hepatotoxicity in Rats , 2019 .
[2] Liang Liu,et al. Baicalein Enhances the Oral Bioavailability and Hepatoprotective Effects of Silybin Through the Inhibition of Efflux Transporters BCRP and MRP2 , 2018, Front. Pharmacol..
[3] Liang Liu,et al. Role of tangeretin as a potential bioavailability enhancer for silybin: Pharmacokinetic and pharmacological studies , 2017, Pharmacological research.
[4] M. Bijak. Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.)—Chemistry, Bioavailability, and Metabolism , 2017, Molecules.
[5] Peter F Surai. Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives , 2015, Antioxidants.
[6] H. Ichijo,et al. Mitochondrial proteolysis: its emerging roles in stress responses. , 2015, Biochimica et biophysica acta.
[7] M. Tuorkey,et al. Cytoprotective effect of silymarin against diabetes-induced cardiomyocyte apoptosis in diabetic rats. , 2015, Biomedical and environmental sciences : BES.
[8] Y. Liu,et al. Silymarin induces cell cycle arrest and apoptosis in ovarian cancer cells. , 2014, European journal of pharmacology.
[9] N. Zeghal,et al. Protective role of silymarin against manganese‐induced nephrotoxicity and oxidative stress in rat , 2014, Environmental toxicology.
[10] S. Cho,et al. Protective effect of silymarin against cisplatin-induced ototoxicity. , 2014, International journal of pediatric otorhinolaryngology.
[11] Debapriya Garabadu,et al. Silibinin pretreatment attenuates biochemical and behavioral changes induced by intrastriatal MPP+ injection in rats , 2014, Pharmacology Biochemistry and Behavior.
[12] Bin Xu,et al. Silybum marianum oil attenuates oxidative stress and ameliorates mitochondrial dysfunction in mice treated with D-galactose , 2014, Pharmacognosy magazine.
[13] V. Křen,et al. Biotransformation of silybin and its congeners. , 2013, Current drug metabolism.
[14] J. Markowitz,et al. An Assessment of Pharmacokinetics and Antioxidant Activity of Free Silymarin Flavonolignans in Healthy Volunteers: A Dose Escalation Study , 2013, Drug Metabolism and Disposition.
[15] P. Portincasa,et al. A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes. , 2013, World journal of gastroenterology.
[16] M. Aschner,et al. Manganese Neurotoxicity: a Focus on Glutamate Transporters , 2013, Annals of Occupational and Environmental Medicine.
[17] G. Subramanya,et al. Antioxidant and Anti-Hepatitis C Viral Activities of Commercial Milk Thistle Food Supplements , 2013, Antioxidants.
[18] S. Witkin,et al. Silibinin attenuates oxidative metabolism and cytokine production by monocytes from preeclamptic women , 2013, Free radical research.
[19] N. Zeghal,et al. Therapeutic efficacy of silymarin from milk thistle in reducing manganese-induced hepatic damage and apoptosis in rats , 2013, Human & experimental toxicology.
[20] L. Calani,et al. Absorption and metabolism of milk thistle flavanolignans in humans. , 2012, Phytomedicine : international journal of phytotherapy and phytopharmacology.
[21] K. Reddy,et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. , 2012, Journal of the American Medical Association (JAMA).
[22] A. C. Santos,et al. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update , 2012, Archives of Toxicology.
[23] N. Nalini,et al. Colon cancer chemopreventive efficacy of silibinin through perturbation of xenobiotic metabolizing enzymes in experimental rats. , 2012, European journal of pharmacology.
[24] R. Saller,et al. The Use of Silymarin in the Treatment of Liver Diseases , 2012, Drugs.
[25] N. Zeghal,et al. Improvement of Cerebellum Redox States and Cholinergic Functions Contribute to the Beneficial Effects of Silymarin Against Manganese-Induced Neurotoxicity , 2011, Neurochemical Research.
[26] P. Chanvorachote,et al. Silymarin selectively protects human renal cells from cisplatin-induced cell death , 2011, Pharmaceutical biology.
[27] Mushir M. Ali,et al. Reassessing bioavailability of silymarin. , 2011, Alternative medicine review : a journal of clinical therapeutic.
[28] V. Křen,et al. Evidence for differences in regioselective and stereoselective glucuronidation of silybin diastereomers from milk thistle (Silybum marianum) by human UDP-glucuronosyltransferases , 2011, Xenobiotica; the fate of foreign compounds in biological systems.
[29] C. Loguercio,et al. Silybin and the liver: from basic research to clinical practice. , 2011, World journal of gastroenterology.
[30] Jianhui Liu,et al. Silibinin: A novel inhibitor of Aβ aggregation , 2011, Neurochemistry International.
[31] D. Abo-Elmatty,et al. Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies. , 2011, European journal of pharmacology.
[32] J. Ježek,et al. Dehydrosilybin attenuates the production of ROS in rat cardiomyocyte mitochondria with an uncoupler-like mechanism , 2010, Journal of bioenergetics and biomembranes.
[33] E. Ernst. The Review of Natural Products , 2010 .
[34] N. Zeghal,et al. Silymarin, a natural antioxidant, protects cerebral cortex against manganese-induced neurotoxicity in adult rats , 2010, BioMetals.
[35] M. Doležal,et al. Substituted Pyrazinecarboxamides as Abiotic Elicitors of Flavolignan Production in Silybum marianum (L.) Gaertn Cultures in Vitro , 2010, Molecules.
[36] Mingzhang Lin,et al. Free radical scavenging reactions and antioxidant activities of silybin: Mechanistic aspects and pulse radiolytic studies , 2009, Free radical research.
[37] X. Leverve,et al. Interrelation between the inhibition of glycolytic flux by silibinin and the lowering of mitochondrial ROS production in perifused rat hepatocytes. , 2008, Life sciences.
[38] P. Haddad,et al. Antioxidant and mitochondrial protective effects of silibinin in cold preservation-warm reperfusion liver injury. , 2008, Journal of ethnopharmacology.
[39] S. J. Schrieber,et al. Pharmacokinetics and Metabolic Profile of Free, Conjugated, and Total Silymarin Flavonolignans in Human Plasma after Oral Administration of Milk Thistle Extract , 2008, Drug Metabolism and Disposition.
[40] Lie-Chwen Lin,et al. Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. , 2007, Journal of pharmaceutical and biomedical analysis.
[41] K. Lemr,et al. Silybin Is Metabolized by Cytochrome P450 2C8 in Vitro , 2007, Drug Metabolism and Disposition.
[42] A. Gescher,et al. Quantitation of silibinin, a putative cancer chemopreventive agent derived from milk thistle (Silybum marianum), in human plasma by high-performance liquid chromatography and identification of possible metabolites. , 2007, Journal of Agricultural and Food Chemistry.
[43] V. Křen,et al. Silybin and silymarin--new and emerging applications in medicine. , 2007, Current medicinal chemistry.
[44] H. Hafez,et al. Silymarin modulates Cisplatin-induced oxidative stress and hepatotoxicity in rats. , 2006, Journal of biochemistry and molecular biology.
[45] C. Girish,et al. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. , 2006, The Indian journal of medical research.
[46] Li‐jun Wu,et al. Silibinin protects rat cardiac myocyte from isoproterenol-induced DNA damage independent on regulation of cell cycle. , 2006, Biological & pharmaceutical bulletin.
[47] A. Dennison,et al. Pilot Study of Oral Silibinin, a Putative Chemopreventive Agent, in Colorectal Cancer Patients: Silibinin Levels in Plasma, Colorectum, and Liver and Their Pharmacodynamic Consequences , 2006, Clinical Cancer Research.
[48] S. Antus,et al. Structure prerequisite for antioxidant activity of silybin in different biochemical systems in vitro. , 2006, Phytomedicine : international journal of phytotherapy and phytopharmacology.
[49] V. Křen,et al. Silybin and silymarin--new effects and applications. , 2005, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.
[50] L. Pérez,et al. Inhibition of rat liver UDP-glucuronosyltransferase by silymarin and the metabolite silibinin-glucuronide. , 2005, Life sciences.
[51] R. Agarwal,et al. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. , 2005, Cancer research.
[52] Y. H. Han,et al. Stereoselective metabolism of silybin diastereoisomers in the glucuronidation process. , 2004, Journal of pharmaceutical and biomedical analysis.
[53] Tianyi Zhang,et al. Application of liquid chromatography-electrospray ionization-ion trap mass spectrometry to investigate the metabolism of silibinin in human liver microsomes. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[54] P. Oliveira,et al. Protection against post-ischemic mitochondrial injury in rat liver by silymarin or TUDC. , 2003, Hepatology research : the official journal of the Japan Society of Hepatology.
[55] S. Thakur. SILYMARIN-A HEPATOPROTECTIVE AGENT , 2002 .
[56] S. Bhattacharya,et al. Effect of Withania somnifera glycowithanolides on iron‐induced hepatotoxicity in rats , 2000, Phytotherapy research : PTR.
[57] R. Agarwal,et al. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. , 1999, Carcinogenesis.
[58] K. Soliman,et al. Food Constituents Attenuate Monoamine Oxidase Activity and Peroxide Levels in C6 Astrocyte Cells , 1998, Planta medica.
[59] H. de Groot,et al. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin , 1996, Hepatology.
[60] H. de Groot,et al. Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. , 1996, Life sciences.
[61] B. Lokesh,et al. Effect of curcumin and eugenol on iron-induced hepatic toxicity in rats. , 1996, Toxicology.
[62] J. Tao,et al. Hepatoprotective properties of Silybum marianum herbal preparation on ethanol-induced liver damage , 1996 .
[63] G. Krumbiegel,et al. Two high-performance liquid chromatographic assays for the determination of free and total silibinin diastereomers in plasma using column switching with electrochemical detection and reversed-phase chromatography with ultraviolet detection. , 1995, Journal of chromatography. B, Biomedical applications.
[64] P. Morazzoni,et al. Silybum marianum (Carduus marianus) , 1995 .
[65] A. Srivastava,et al. Effect of picroliv and silymarin on liver regeneration in rats , 1994 .
[66] H. Mascher,et al. Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. , 1992, International journal of clinical pharmacology, therapy, and toxicology.
[67] V. Fintelmann. Modern phytotherapy and its uses in gastrointestinal conditions. , 1991, Planta medica.
[68] G. Labbe,et al. Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice. Evidence that silymarin acts both as an inhibitor of metabolic activation and as a chain-breaking antioxidant. , 1990, Biochemical pharmacology.
[69] D. Lorenz,et al. Pharmacokinetic studies with silymarin in human serum and bile. , 1984, Methods and findings in experimental and clinical pharmacology.
[70] P. Flory,et al. [Studies on elimination of silymarin in cholecystectomized patients. I. Biliary and renal elimination after a single oral dose]. , 1980, Planta medica.
[71] J. Meldolesi,et al. Liver protection by silymarin: in vitro effect on dissociated rat hepatocytes. , 1976, Arzneimittel-Forschung.
[72] A. Desplaces,et al. The effects of silymarin on experimental phalloidine poisoning. , 1975, Arzneimittel-Forschung.
[73] C. Panne,et al. [Searching for a new therapeutic principle. Experience with hepatic therapeutic agent Legalon]. , 1969, Die Medizinische Welt.